+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Selective Estrogen Receptor"

ER+/HER2 -ve Breast Cancer - Pipeline Insight, 2021 - Product Thumbnail Image

ER+/HER2 -ve Breast Cancer - Pipeline Insight, 2021

  • Clinical Trials
  • February 2021
  • 60 Pages
  • Global
From
Atrophic Vaginitis - Pipeline Insight, 2021 - Product Thumbnail Image

Atrophic Vaginitis - Pipeline Insight, 2021

  • Clinical Trials
  • January 2021
  • 60 Pages
  • Global
From
From
From
Estrogen Receptor - Pipeline Review, H2 2019 - Product Thumbnail Image

Estrogen Receptor - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 91 Pages
  • Global
From
Global Breast Cancer Drug Market & Clinical Trial Insight 2025 - Product Thumbnail Image

Global Breast Cancer Drug Market & Clinical Trial Insight 2025

  • Clinical Trials
  • January 2020
  • 1140 Pages
  • Global
From
From
From
From
Loading Indicator

The Selective Estrogen Receptor Modulators (SERMs) market is a subset of the Women's Health market, focusing on the use of SERMs to treat a variety of conditions related to female reproductive health. SERMs are a type of drug that can act as either an agonist or antagonist of the estrogen receptor, depending on the tissue type. This allows them to be used to treat conditions such as endometriosis, uterine fibroids, and menopausal symptoms. SERMs can also be used to reduce the risk of breast cancer and osteoporosis. SERMs are available in both oral and topical forms, and are often used in combination with other treatments. They are generally considered to be safe and effective, with few side effects. Some companies in the SERMs market include Pfizer, Novartis, AstraZeneca, and Eli Lilly. Show Less Read more